Research Topics
Species | Craig H MoskowitzSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapyCraig Moskowitz
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Cancer Chemother Pharmacol 49:S9-12. 2002..Novel treatment strategies designed to increase their complete response rate would be anticipated to improve their long-term survival...- Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantationDorothy Pan
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer J 8:371-6. 2002..DISCUSSION: Rituximab is effective and well-tolerated palliative treatment for aggressive non-Hodgkin's lymphomas that relapse after or is refractory to autologous stem cell transplantation... - Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999Paul A Hamlin
Medicine Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Br J Haematol 130:691-9. 2005.... 
Interim PET-CT in the management of diffuse large B-cell lymphomaCraig H Moskowitz
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Hematology Am Soc Hematol Educ Program 2012:397-401. 2012....- Diffuse large B cell lymphoma: how can we cure more patients in 2012?Craig Moskowitz
Division of Hematologic Oncology, Lymphoma and Adult BMT Services, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, United States
Best Pract Res Clin Haematol 25:41-7. 2012.... - Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphomaCraig H Moskowitz
Lymphoma Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Blood 119:1665-70. 2012..6% for patients with a positive scan (P < .001). This prospective study provides evidence that the goal of SLT in patients with Hodgkin lymphoma should be a negative FDG-PET scan before HDT/ASCT... - Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphomaC H Moskowitz
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 4:311-6. 1998..Alternative approaches, such as ex vivo expansion or the use of other growth factors in addition to G-CSF, may improve mobilization of progenitor cells for PBPC transplantation... - High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imagingCraig H Moskowitz
Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Br J Haematol 148:890-7. 2010..61. Risk-adapted augmentation of salvage treatment in patients with HL is feasible and improves EFS in poorer-risk patients. Our data suggest that normalisation of FI pre-ASCT predicts outcome, and should be the goal of salvage treatment... - An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphomaCraig H Moskowitz
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Natl Compr Canc Netw 8:347-52. 2010.... - Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphomaC H Moskowitz
Hematology Service, New York, NY, USA
Ann Oncol 18:1842-50. 2007..We incorporated a thrombopoietic agent into the ICE chemotherapy program to potentially: decrease platelet associated toxicities, augment stem cell collection and maintain dose intensity... - Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphomaCraig H Moskowitz
Departments of Medicine, Radiology, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
J Clin Oncol 28:1896-903. 2010..Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy... - Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantationC H Moskowitz
Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Ann Oncol 17:iv37-9. 2006.... - Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCLCraig H Moskowitz
Lymphoma and Hematology Services of the Division of Hematological Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Blood 106:3383-5. 2005..The cell of origin as determined by IHC does not predict outcome in transplantation-eligible patients with relapsed or primary refractory DLBCL... - Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's diseaseCraig H Moskowitz
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, PO Box 350, New York, NY 10021, USA
Br J Haematol 124:645-52. 2004..001). While patients with chemosensitive disease have an excellent outcome with HDT and ASCT, novel approaches are needed to cure HD patients who fail front-line and second-line chemotherapy... - Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphomaPaul A Hamlin
Lymphoma and Hematology Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Box 350, 1275 York Ave, New York, NY, 10021
Blood 102:1989-96. 2003..This powerful prognostic instrument should be used to evaluate new treatment approaches and to compare results of different regimens... - Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaTarun Kewalramani
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Blood 103:3684-8. 2004..25). RICE appears to induce very high CR rates in patients with relapsed and refractory DLBCL; however, further studies are necessary to determine whether this treatment regimen will improve outcomes after ASCT... - Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphomaAlison J Moskowitz
Lymphoma Service of the Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Blood 116:4934-7. 2010..055). Studies evaluating novel STs, conditioning regimens, post-ASCT maintenance, or allogeneic stem cell transplantation are warranted for patients who fail to normalize pre-ASCT functional imaging... - Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphomaJohn Gerecitano
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, USA
Clin Cancer Res 17:2493-501. 2011.... - R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacyJeffrey L Halaas
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Leuk Lymphoma 46:541-7. 2005..Whether adding rituximab and increasing dose intensity improves survival over either alone will require randomized studies... - Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignanciesOwen A O'Connor
Lymphoid Development and Malignancy Program, Lymphoma Service, Columbia University, Herbert Irving Comprehensive Cancer Center, 1130 St Nicholas Ave, New York, NY 10032, USA
J Clin Oncol 27:4357-64. 2009..To determine the maximum-tolerated dose (MTD) and efficacy of pralatrexate in patients with lymphoma... 
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaAlison J Moskowitz
Medical Oncology Hematology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 8, New York, NY 10065, USA
Br J Haematol 146:158-63. 2009..Future studies should focus on prospectively evaluating RIT following HDT-ASCT failure in patients with remission duration from HDT-ASCT of >6 months...- Phase II study of bendamustine in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz
Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
J Clin Oncol 31:456-60. 2013..Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL). This phase II study evaluated the efficacy of bendamustine in relapsed and refractory HL... - Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphomaKaryn A Goodman
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 26:5240-7. 2008.... - Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphomaTarun Kewalramani
Hematology Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Br J Haematol 134:202-7. 2006..The outcome of ASCT for patients with chemosensitive relapsed or primary refractory PTCL is similar to that for patients with DLBCL... - High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphomaDaniel O Persky
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Appl Immunohistochem Mol Morphol 18:35-40. 2010..We sought to determine if we could identify such markers, and if our comprehensive second-line program could overcome their significance... - Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicityBradford S Hoppe
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10165, USA
J Clin Oncol 26:1858-64. 2008..To analyze outcome, prognostic factors, and toxicities in patients with diffuse large-cell lymphoma (DLCL) who received involved-field radiotherapy (IFRT) before high-dose chemotherapy with autologous stem-cell rescue (ASCR)... - Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphomaOwen A O'Connor
Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10032, USA
Br J Haematol 139:425-8. 2007..For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL... - Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysisLauren E Abrey
Departments of Neurology and Medicine and the Office of Clinical Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 21:4151-6. 2003..To assess the safety and efficacy of intensive methotrexate-based chemotherapy followed by high-dose chemotherapy (HDT) with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma (PCNSL)... - Controversies in the treatment of lymphoma with autologous transplantationAlison J Moskowitz
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Oncologist 14:921-9. 2009.... - The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphomaAashiyana F Koreishi
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Appl Immunohistochem Mol Morphol 18:206-11. 2010..0001). Expression of cytotoxic and regulatory T-cells shows prognostic significance in the relapsed/refractory clinical setting of cHL... - Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphomaQianxun Xiao
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Appl Immunohistochem Mol Morphol 12:211-5. 2004..Our results demonstrate that there is differential c-REL protein expression in cHL in comparison with NLPHL and suggest that c-REL may play a role in the pathogenesis of classic Hodgkin lymphoma... - Mantle cell lymphomasCraig H Moskowitz
Weill Medical College, Cornell University, New York, USA
Clin Adv Hematol Oncol 3:suppl 6-7. 2005 - Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantationTrudy N Small
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Biol Blood Marrow Transplant 15:1538-42. 2009..5microg of PT induces an inadequate response. Prospective trials evaluating BOOSTRIX, containing 8microg/dose of PT (approved for adults in December 2008) are warranted in this vulnerable population undergoing transplantation... - Randomized clinical trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic stem-cell transplantationKatherine N DuHamel
Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 28:3754-61. 2010..We report results of a randomized clinical trial that tested the effects of a 10-session, telephone-administered cognitive-behavioral therapy (CBT) intervention on PTSD, depression, and distress symptoms... - CD5 negative, Cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleenJulie Teruya-Feldstein
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Appl Immunohistochem Mol Morphol 17:255-8. 2009..The patient received multiple therapies and ultimately died. This case raises the differential diagnoses of pleomorphic mantle cell lymphoma and other aggressive lymphomas with pleomorphic, anaplastic, and Reed-Sternberg-like cells...